Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Pharmacological Trial to Evaluate the Safety of Miglustat Administration in Subjects With Spastic Paraplegia 11 (TreatSPG11)

NCT04768166 is registered in ClinicalTrials.gov with IRCCS Fondazione Stella Maris as lead sponsor.

NCT NCT04768166
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04768166 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Pharmacological Trial to Evaluate the Safety of Miglustat Administration in Subjects With Spastic Paraplegia 11 (TreatSPG11)
Lead sponsor
IRCCS Fondazione Stella Maris
Phase
Phase 2
Overall status
Completed
Start date
June 15, 2021
Completion date
September 15, 2021
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hereditary spastic paraparesis